Literature DB >> 16962862

Prevention of mortality from hepatitis B and hepatitis C.

Eugene R Schiff1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16962862     DOI: 10.1016/S0140-6736(06)69347-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.

Authors:  Young-Suk Lim; Ji-Young Lee; Danbi Lee; Ju Hyun Shim; Han Chu Lee; Yung Sang Lee; Dong Jin Suh
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

2.  Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center.

Authors:  M Demir; J Nigemeier; F Kütting; A Bowe; C Schramm; V Hoffmann; D Waldschmidt; T Goeser; H-M Steffen
Journal:  Infection       Date:  2015-02-21       Impact factor: 3.553

3.  Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study.

Authors:  Guangbi Yao; Chengwei Chen; Weilun Lu; Hong Ren; Deming Tan; Yuming Wang; Daozheng Xu; Jessica Liu; Dong Xu; Cyril Llamoso
Journal:  Hepatol Int       Date:  2008-08-30       Impact factor: 6.047

4.  Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication.

Authors:  Jin-Gang Gu; Cheng-liang Zhu; Duo-zhi Cheng; Yan Xie; Fang Liu; Xin Zhou
Journal:  Lipids Health Dis       Date:  2011-08-29       Impact factor: 3.876

5.  Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.

Authors:  Jihyun An; Young-Suk Lim; Gi-Ae Kim; Seong-Bong Han; Wonhee Jeong; Danbi Lee; Ju Hyun Shim; Han Chu Lee; Yung Sang Lee
Journal:  BMC Gastroenterol       Date:  2017-01-19       Impact factor: 3.067

6.  Compound Biejia-Ruangan tablet as an adjunctive therapy to entecavir for chronic hepatitis B complicated with hepatic fibrosis: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Yong-Hong Xu; Chuan Xue
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 7.  Viruses and human cancer.

Authors:  John B Liao
Journal:  Yale J Biol Med       Date:  2006-12

8.  Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray.

Authors:  Doo Hyun Kim; Hong Seok Kang; Seong-Suk Hur; Seobo Sim; Sung Hyun Ahn; Yong Kwang Park; Eun-Sook Park; Ah Ram Lee; Soree Park; So Young Kwon; Jeong-Hoon Lee; Kyun-Hwan Kim
Journal:  Gut Liver       Date:  2018-05-15       Impact factor: 4.519

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.